Abstract
The new generation of microbicide candidates is based on the use of antiretroviral (ARV) drugs. The first compounds tested were selected among ARV classes that block the early stages of viral replication cycle, either entry/fusion or reverse transcription. Recently, an additional class of ARVs acting on a later step of viral replication has entered the microbicide pipeline, the protease inhibitors (PIs). This class of ARVs has shown strong potency in highly active antiretroviral therapy (HAART) against human immunodeficiency-1 virus (HIV-1) and lower levels of induced resistance compared to other ARV classes. As candidate microbicides, PIs will have to follow the guiding principles of microbicides being effective, safe, user-friendly and affordable. Hence, aspects including antiviral potency, adverse effects in mucosal tissues, formulation, pharmacology at mucosal sites, emergence of resistance, will have to be considered in the design of a PI-based microbicide. In addition, PIs will have to be tested for their capacity to be used in combination-based microbicides with other ARV classes and in combination with other preventive strategies, such as HIV-1 vaccines. Microbicides containing HIV PIs could also be potentially used against other pathologies specific to the female and/or male genital tract or colorectum.
Keywords: Protease inhibitors, saquinavir, ritonavir, lopinavir, darunavir, microbicides, tissue explants, HIV-1, ARV, HIV-infection
Current HIV Research
Title: Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Volume: 10 Issue: 1
Author(s): Carolina Herrera and Robin J. Shattock
Affiliation:
Keywords: Protease inhibitors, saquinavir, ritonavir, lopinavir, darunavir, microbicides, tissue explants, HIV-1, ARV, HIV-infection
Abstract: The new generation of microbicide candidates is based on the use of antiretroviral (ARV) drugs. The first compounds tested were selected among ARV classes that block the early stages of viral replication cycle, either entry/fusion or reverse transcription. Recently, an additional class of ARVs acting on a later step of viral replication has entered the microbicide pipeline, the protease inhibitors (PIs). This class of ARVs has shown strong potency in highly active antiretroviral therapy (HAART) against human immunodeficiency-1 virus (HIV-1) and lower levels of induced resistance compared to other ARV classes. As candidate microbicides, PIs will have to follow the guiding principles of microbicides being effective, safe, user-friendly and affordable. Hence, aspects including antiviral potency, adverse effects in mucosal tissues, formulation, pharmacology at mucosal sites, emergence of resistance, will have to be considered in the design of a PI-based microbicide. In addition, PIs will have to be tested for their capacity to be used in combination-based microbicides with other ARV classes and in combination with other preventive strategies, such as HIV-1 vaccines. Microbicides containing HIV PIs could also be potentially used against other pathologies specific to the female and/or male genital tract or colorectum.
Export Options
About this article
Cite this article as:
Herrera Carolina and J. Shattock Robin, Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides, Current HIV Research 2012; 10 (1) . https://dx.doi.org/10.2174/157016212799304607
DOI https://dx.doi.org/10.2174/157016212799304607 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Microbicides for Prevention of Transmission of Sexually Transmitted Diseases
Current Pharmaceutical Design Transcervical Oropharyngectomy: A Clinically Focused Review
Current Cancer Therapy Reviews Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience The Therapeutic Properties of Carapa guianensis
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals
Current Pharmaceutical Design Counselling and Cognitive Behaviour Interventions Delivered to Reduce Psychological Morbidity and Improve Quality of Life in Gynaecological Cancer Patients: Recent Achievements
Current Women`s Health Reviews Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism